A Phase II Study of Erlotinib monotherapy for patients with non-small cell lung cancer wihtout EGFR mutatio
- Conditions
- on-small cell lung cancer
- Registration Number
- JPRN-UMIN000004207
- Lead Sponsor
- Hokuriku Lung Cancer Study Group
- Brief Summary
patients are recruiting
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Not provided
1) severe interstitial lung disease or pulmonary fibrosis. 2) patient with history of drug-related lung disease. 3) Severe drug allrgy. 4) Patients with complication of infectious disease. 5) patients with Severe diarrhea 6) Patients with clinically significant ball disease. 7) patients with clinically significant opthalmologic disorder. 8) patients with complication or hisotry of gastrointestinal perforation. 9) Uncontrolable GI ulcer. 10) Brain metastasis with symptoms 11) Active multiple cancer. 12) patients with clinically significant heart disease. 13) Patients with clinically siginificant psychologic disease. 14) Patients with lactation or pregnancy. 15) patients who are considered ineligible based on decision of a reasonable investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease contorol rate
- Secondary Outcome Measures
Name Time Method Response rate Overall survival Progression free survival Safety Time to treatment failure